Melissa Davis
In the meantime, Caremark has started to feel some backlash from its legal problems already. Last week, the Orange County Register reported, a local government agency rejected a contract from Caremark, in part because of the "rash of lawsuits" facing the company.
Similarly, in New York -- a state with no connection to the Medicaid probe -- a county legislator said he was "bothered" by Caremark's legal problems even though he recently voted to do business with the company, anyway, the Times Union of Albany, N.Y., reported. Meanwhile, back in North Carolina -- a state that's now eligible to join the whistleblower lawsuit -- Rushing is having second thoughts about his own vote in favor of the company. The Medicaid fraud investigation has given him some pause. But a separate whistleblower complaint, accusing Caremark of selling returned blood products, worries him even more. Rushing says he wouldn't even want his livestock -- let alone his family or neighbors -- to wind up with drugs like that. Thus, he says, he would like to see the commission reconsider its recent Caremark decision so that he can at least vote against the measure even if it passes without him. "We know about these allegations," he told TheStreet.com on Friday. "What's going to happen when somebody includes Union County in a lawsuit? We can't afford that. ... It scares me to death."TheStreet Premium Services
Jim Cramer's Action Alerts PLUS:
Trade right alongside a Wall Street pro — enjoy access to his Charitable Trust portfolio and be sent trade alerts BEFORE he makes a move. Learn MoreOptionsProfits:
Get 50+ trade ideas a week from the industry's top options experts. Plus — exclusive commentary on market trends and essential trading tools. Learn MoreReal Money:
Our team of professional Wall Street Pros — including Jim Cramer, Doug Kass, and Nicholas Vardy — delivers intelligent analysis, timely trade ideas, and colorful commentary. Learn MoreStocks Under $10:
Break into the market with small- and mid-cap stocks... all $10 or less! David Peltier tells you exactly which low-priced stocks he's buying and selling. Learn MoreTo begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
blog comments powered by Disqus
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note |
|
|---|---|---|---|---|
| 12,419.86 | 1,313.32 | 2,837.36 | 16.25 |
Oil *
103.00
|
|
DOWN
160.83 |
DOWN
19.10 |
DOWN
33.63 |
DOWN
1.06 |
10 Yr
1.62%
SPDR Gold
151.91
|
|
-1.28%
|
-1.43%
|
-1.17%
|
-6.12%
|
Data delayed 20 minutes |


Connect with TheStreet